MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Asco

MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced that interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (GBM) will be presented during a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, in Chicago.

Read full article

More news